San Francisco, CA (PRWEB) October 27, 2016 -- Avexegen Therapeutics Inc. (the Company), an innovative biotechnology company developing novel therapies for gastrointestinal disorders, today announced that it has received an award of $225,000 under the National Institutes of Health’s Small Business Innovation Research Program (SBIR) for the development of therapies for inflammatory bowel disease including Crohn’s disease and ulcerative colitis.
More than 1.4 million people in North America suffer chronically with Crohn’s disease and ulcerative colitis, and for many the diseases are not well controlled with currently available therapies. Avexegen will use the NIH grant to advance the development of their lead drug candidate, Neuregulin-4 (NRG-4) by exploring different routes of drug delivery. Multiple preclinical proof-of-concept studies have revealed that NRG-4 has direct biological effects, simultaneously suppressing pro-inflammatory cytokines while driving the healing of damaged and inflamed epithelial tissue. “We believe that NRG-4, with its unique dual mode of action, has the potential to be a first-in-class therapy that may further improve patient care and long term outcomes.” said Artin Asadourian, CEO of Avexegen Therapeutics.
About Avexegen Therapeutics, Inc.
Avexegen, founded in December 2014, is an emerging privately held biotech company based in San Francisco, CA focused on developing novel treatments for gastrointestinal disorders. For more information please visit http://www.avexegen.com
This research is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R43DK112435. The content is solely the responsibility of the company and does not necessarily represent the official views of the National Institutes of Health.
Artin Asadourian, Avexegen Therapeutics, Inc., http://www.Avexegen.com, +1 (818) 288-6200, [email protected]
SOURCE Avexegen Therapeutics, Inc.